Hot Value Stocks To Own Right Now

Palo Alto Networks (NYSE:PANW) had its target price raised by Credit Suisse Group from $150.00 to $175.00 in a report released on Tuesday morning. They currently have an underweight rating on the network technology company’s stock.

PANW has been the subject of a number of other research reports. Robert W. Baird lifted their price objective on shares of Palo Alto Networks from $190.00 to $216.00 and gave the company a neutral rating in a report on Tuesday. Deutsche Bank lifted their price objective on shares of Palo Alto Networks from $180.00 to $210.00 and gave the company a buy rating in a report on Tuesday, February 27th. ValuEngine upgraded shares of Palo Alto Networks from a hold rating to a buy rating in a report on Monday, April 2nd. Susquehanna Bancshares upgraded shares of Palo Alto Networks from a neutral rating to a positive rating and dropped their price objective for the company from $150.00 to $145.00 in a report on Wednesday, February 21st. Finally, KeyCorp lifted their price objective on shares of Palo Alto Networks from $170.00 to $190.00 and gave the company an overweight rating in a report on Monday, February 5th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and thirty-seven have issued a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $198.68.

Hot Value Stocks To Own Right Now: Frequency Electronics Inc.(FEIM)

Advisors’ Opinion:

  • [By Joseph Griffin]

    News articles about Frequency Electronics (NASDAQ:FEIM) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Frequency Electronics earned a news impact score of 0.15 on Accern’s scale. Accern also assigned media headlines about the communications equipment provider an impact score of 46.4556074629456 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Hot Value Stocks To Own Right Now: Pluristem Therapeutics Inc.(PSTI)

Advisors’ Opinion:

  • [By Max Byerly]

    Momenta Pharmaceuticals (NASDAQ: MNTA) and Pluristem Therapeutics (NASDAQ:PSTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

  • [By Stephan Byrd]

    Pluristem Therapeutics Inc. (NASDAQ:PSTI) has been given a consensus recommendation of “Buy” by the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $4.00.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Value Stocks To Own Right Now: Nuance Communications Inc.(NUAN)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Nuance Communications (NASDAQ:NUAN) had its price objective cut by Stifel Nicolaus from $18.00 to $15.00 in a report issued on Thursday. The brokerage currently has a “hold” rating on the software maker’s stock. Stifel Nicolaus’ target price indicates a potential upside of 15.03% from the company’s current price.

  • [By Dan Caplinger]

    One key part of the rush toward artificial intelligence is making sure that automated systems can communicate easily and effectively with their human users. Nuance Communications (NASDAQ:NUAN) has a huge head start in voice recognition technology, and despite its successes in areas like medical transcription, the tech company knows that in order to sustain its competitive advantage, it needs to use its lead to push forward with groundbreaking technological innovations.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    MDC Partners Inc. (NASDAQ: MDCA) fell 23.4 percent to $5.25 in pre-market trading after a first-quarter earnings miss.
    Hudson Technologies Inc. (NASDAQ: HDSN) shares fell 15.1 percent to $3.48 in pre-market trading after the company reported downbeat Q1 earnings.
    Nuance Communications, Inc. (NASDAQ: NUAN) fell 14 percent to $13.15 in pre-market trading after the company posted downbeat Q2 earnings and lowered FY18 organic growth guidance.
    Myomo, Inc. (NYSE: MYO) fell 13.2 percent to $3.10 in pre-market trading after reporting downbeat quarterly results.
    Rowan Companies plc (NYSE: RDC) shares fell 10.7 percent to $14.13 in pre-market trading after climbing 8.50 percent on Wednesday.
    BT Group plc (NYSE: BT) fell 9 percent to $14.80 in pre-market trading after the company reported Q4 results and announced plans to cut 13,000 jobs over the next three years.
    Exelixis, Inc. (NASDAQ: EXEL) fell 8.3 percent to $19.90 in pre-market trading after the company disclosed that IMblaze370 Phase 3 pivotal trial of atezolizumab and cobimetinib in patients with heavily pretreated locally advanced or metastatic colorectal cancer did not meet primary endpoint.
    Infinera Corporation (NASDAQ: INFN) fell 8.2 percent to $10.80 in pre-market trading after reporting Q1 results.
    Synaptics, Incorporated (NASDAQ: SYNA) shares fell 7.4 percent to $43.00 in pre-market trading. Synaptics reported better-than-expected earnings for its third quarter, while sales missed estimates.
    Randgold Resources Limited (NASDAQ: GOLD) shares fell 7.4 percent to $76.23 in pre-market trading after reporting Q1 earnings.
    Integra LifeSciences Holdings Corporation (NASDAQ: IART) shares fell 7 percent to $59.36 in pre-market trading. Integra LifeSciences priced its 5.25 million share public offering of common stock at $58.50 per share.
    Array BioPharma Inc. (NASDAQ: ARRY) shares fell 6.9 percent to $12.75 in pre-m

  • [By Ethan Ryder]

    Shares of Nuance Communications Inc. (NASDAQ:NUAN) have been assigned a consensus recommendation of “Buy” from the twelve brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $20.25.

  • [By Paul Ausick]

    Nuance Communications Inc. (NASDAQ: NUAN) dropped about 20% Thursday to post a new 52-week low of $12.19. Shares closed at $15.28 on Wednesday and the stock’s 52-week high is $19.49. Volume of around 19 million shares was about nine times the daily average. The company reported indifferent results Wednesday night but cut its outlook for revenue growth.

Hot Value Stocks To Own Right Now: GTx Inc.(GTXI)

Advisors’ Opinion:

  • [By Chris Lange]

    GTx Inc. (NASDAQ: GTXI) will present additional data demonstrating duration of response following completion of treatment for its Phase 2 proof-of-concept clinical trial evaluating enobosarm 3 mg in postmenopausal women with stress urinary incontinence at the upcoming 2018 American Urological Association meeting on May 18.

  • [By Stephan Byrd]

    GTx, Inc. (NASDAQ:GTXI) was down 6.4% during mid-day trading on Friday after an insider sold shares in the company. The company traded as low as $17.10 and last traded at $17.30. Approximately 726,400 shares traded hands during trading, an increase of 492% from the average daily volume of 122,740 shares. The stock had previously closed at $18.49.

  • [By Ethan Ryder]

    GTx, Inc. (NASDAQ:GTXI) insider Jason T. Shackelford sold 9,279 shares of the business’s stock in a transaction dated Wednesday, June 20th. The stock was sold at an average price of $19.01, for a total transaction of $176,393.79. Following the sale, the insider now directly owns 19,453 shares in the company, valued at $369,801.53. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Hot Value Stocks To Own Right Now: Brandywine Realty Trust(BDN)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Brandywine Realty Trust (NYSE:BDN) by 5.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 168,439 shares of the real estate investment trust’s stock after buying an additional 8,253 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned about 0.09% of Brandywine Realty Trust worth $2,675,000 at the end of the most recent reporting period.

  • [By Max Byerly]

    ILLEGAL ACTIVITY WARNING: “Brandywine Realty Trust (BDN) Issues FY18 Earnings Guidance” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at www.tickerreport.com/banking-finance/3371791/brandywine-realty-trust-bdn-issues-fy18-earnings-guidance.html.

  • [By Ethan Ryder]

    BNP Paribas Arbitrage SA raised its stake in Brandywine Realty Trust (NYSE:BDN) by 18.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,507 shares of the real estate investment trust’s stock after buying an additional 5,861 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in Brandywine Realty Trust were worth $596,000 at the end of the most recent quarter.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Brandywine Realty Trust (BDN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Brandywine Realty Trust (NYSE:BDN) has received an average rating of “Hold” from the nine analysts that are presently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $18.00.

Leave a Reply

Your email address will not be published. Required fields are marked *